{"id":"NCT01499953","sponsor":"GWT-TUD GmbH","briefTitle":"Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux","officialTitle":"Superficial Vein Thrombosis (SVT) Treated for Forty-five Days With Rivaroxaban Versus Fondaparinux","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2016-05","completion":"2016-05","firstPosted":"2011-12-26","resultsPosted":"2023-05-15","lastUpdate":"2023-05-15"},"enrollment":472,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Superficial Vein Thrombosis"],"interventions":[{"type":"DRUG","name":"Rivaroxaban","otherNames":["Xarelto"]},{"type":"DRUG","name":"Fondaparinux","otherNames":["Arixtra"]}],"arms":[{"label":"Rivaroxaban","type":"EXPERIMENTAL"},{"label":"Fondaparinux","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of rivaroxaban versus fondaparinux in the treatment of superficial vein thrombosis (SVT).","primaryOutcome":{"measure":"Rate of Objectively Confirmed VTE Complications","timeFrame":"45 +/- 5 days","effectByArm":[{"arm":"Rivaroxaban","deltaMin":7,"sd":null},{"arm":"Fondaparinux","deltaMin":4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0252"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":31},"locations":{"siteCount":23,"countries":["Germany"]},"refs":{"pmids":["33368114","28219692","26973347"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":235},"commonTop":[]}}